Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||AZD7762 + Irinotecan|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AZD7762||AZD-7762||CHK Inhibitor (Pan) 2||AZD7762 is an ATP-competitive CHK1/CHK2 inhibitor, which abrogates DNA damage-induced cell cycle checkpoints, and demonstrates antitumor activity when administered in combination with DNA-damaging agents (PMID: 18790776, PMID: 32335582, PMID: 31372095).|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 10||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|